These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23103384)

  • 1. Quantification of ER/PR expression in ovarian low-grade serous carcinoma.
    Escobar J; Klimowicz AC; Dean M; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Köbel M
    Gynecol Oncol; 2013 Feb; 128(2):371-6. PubMed ID: 23103384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
    Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
    Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
    Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.
    May T; Shoni M; Crum CP; Xian W; Vathipadiekal V; Birrer M; Rosen B; Tone A; Murphy KJ
    Gynecol Oncol; 2013 Mar; 128(3):488-92. PubMed ID: 23253401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
    Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
    Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
    Liu JF; Hirsch MS; Lee H; Matulonis UA
    Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of heat shock protein-70, estrogen receptor and progesterone receptor in ovarian carcinomas and the correlation between HSP70 and sex steroid receptor].
    Xing Y; Tang Z; Liao Y; Zhu SF; Li ZM; Chen ML
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jul; 35(4):486-8. PubMed ID: 15291106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY; Xi MR; Yang KX; Yu H
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF; He LS; Zhang ZD; Huang QS
    Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
    Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
    Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
    Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
    Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.